In this regard, it is worth noting that there are inhibitors to known TBX2 co-factors (e.g. HDAC1/2 and Sp1) and upstream regulators (e.g. PI3K/AKT and Wnt/β-catenin) that are already FDA-approved or currently undergoing clinical evaluation for their therapeutic potential in cancer treatment. This evidence concerns the gene HDAC1 and cancer.